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Abstract
Objective: The somatic point mutation in the BRAF gene, which results in a valine-to-glutamate sub-
stitution at residue 600 (BRAFV600E), is an ideal hallmark of papillary thyroid carcinoma (PTC). How-
ever, its prevalence is varyingly reported in different studies, and its expression in the follicular variant
PTC is controversial, reducing its potential usefulness as diagnostic marker.
Design and methods: We developed an assay based on mutant allele-specific PCR amplification (MASA)
to detect BRAF mutation. We compared the sensitivity of MASA, single-strand conformation poly-
morphism (SSCP) and direct DNA sequencing of PCR products. Then, we used MASA 78 to analyze
78 archival thyroid tissues, including normal samples, follicular adenomas, follicular carcinomas and
PTC.
Results: The MASA assay proved to be a more sensitive method than SSCP and DNA sequencing of
PCR products. BRAF mutation was found by MASA in 19/43 (44.2%) of PTC, including 14/31
(45.2%) classic forms and 5/12 (41.7%) follicular variants. No mutations of BRAF were detected
in the normal thyroid tissues, nor in follicular adenomas or follicular carcinomas. No correlation
was found between BRAF mutation and clinicopathologic features nor with recurrence during a post-
operative follow-up period of 4–11 years. BRAFV600E significantly correlated with absence of node
metastasis.
Conclusions: BRAFV600E is present in PTC, both in the classic form and in follicular variant with simi-
lar prevalence. No correlation was found between BRAF mutation and aggressive clinical behavior.
MASA-PCR proved to be a specific, sensitive and reliable method to detect BRAF T1799A in DNA
extracted from different sources, including cytologic samples obtained either fresh or from archival
glass slides. We propose this method as a useful tool to improve accuracy of preoperative diagnosis
identifying PTC from biopsies with indeterminate cytologic findings.
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Introduction
The tyrosine kinase receptor/RAS/RAF/MEK/ERK cas-
cade is a key regulator of cell growth in all eukaryotic
cells. Upon activation, ERK phosphorylates cytoplasmic
targets (such as RSK and MNK) and translocates to the
nucleus, where it stimulates the activity of various tran-
scription factors, leading to activation of the cell cycle
(1). In papillary thyroid cancers, aberrant expression of
genes coding for the kinase domain of RET or TRK tyro-
sine kinase receptors, and activating mutations of RAS,
are present and all lead to RAF activation. Thus, RAF
plays a pivotal role in transformation, as it connects aber-
rant activating signals to cell-cycle machinery.
The family of v-RAF-related genes comprises three
serine/threonine kinase isoforms, A-RAF, B-RAF- and
C-RAF- (or RAF-1), that display both overlapping and
unique functions (2–7).
The thymine-to-adenine transversion at nucleotide
position 1799 of BRAF, which results in a valine-
to-glutamate substitution at residue 600 (BRAFV600E
formerly position 1796 and residue V599E), occurs in
a broad range of human cancers (8–14). This somatic
point mutation in the BRAF gene has been identified as
the most common genetic event in papillary thyroid
carcinoma (PTC) (15–24).
Although this mutation has consistently been
reported to be specific for PTC, no benign thyroid
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neoplasms or follicular carcinomas have been found to
harbor BRAF mutation, and its prevalence in PTC is
quite variable (29–69%) (Table 1).
Because it offers good sensitivity and specificity as
molecular marker of PTC, detection of BRAF mutation
on FNAB specimens has been proposed as a diagnostic
adjunctive tool in evaluation of thyroid nodules with
indeterminate cytologic findings (25–27).
Uncertain prevalence might bias the potential useful-
ness of the detection of BRAF mutation on FNAB speci-
mens. The sensitivity of detection of BRAF T1799A
transversion mutation as diagnostic marker for PTC on
FNAB specimens depends on its prevalence and on the
technique employed. Genomic amplification by PCR, fol-
lowed by single-strand conformation polymorphism
(SSCP) and validation of the results by DNA sequencing,
is the method usually employed to detect BRAF T1799A
transversion mutation. Alternative methods proposed
are real-time allele-specific amplification, colorimetric
mutation detection, and restriction fragment length
polymorphism (RFLP) (26, 28, 29). With the exception
of real-time allele-specific amplification, these assays
are time-consuming and not always sensitive enough
to detect the low percentage of cells containing the
mutation. This second limitation might be of great rel-
evance when investigating heterogeneous tissue speci-
mens. Therefore, we developed an assay based on
mutant allele-specific amplification (MASA) to detect
BRAF T1799A transversion mutation in DNA extracted
from fine-needle aspiration biopsy (FNAB) or from
archived paraffin-embedded thyroid tissue. Our results,
comparing SSCP, direct DNA sequencing and MASA,
demonstrate that MASA is a specific and reliable
approach to improve the detection of BRAF mutation.
Materials and methods
Tumor samples and cell lines
Paraffin-embedded blocks were retrieved from the files of
the relevant department (Scienze Biomorfologiche e
Funzionali) at the University of Naples, Italy. All tissues
had been routinely fixed overnight in buffered formalin.
We analyzed 43 papillary carcinomas, 27 follicular
carcinomas and three follicular adenomas for BRAF
mutation; in addition, five specimenswith unremarkable
morphology obtained from the lobe contralateral to the
tumor in total thyroidectomy samples were also pro-
cessed. Standard criteria were employed to classify
tumors and their variants (30). Twelve were assigned
to the follicular variant and separated from PTCs show-
ing classic features (n ¼ 31); special care was also
taken to select from the files only cases of follicular
cancer with unquestionable evidence of vascular
invasion (n ¼ 27), and to exclude follicular or papillary
tumors with oxyphilic changes. All benign and malig-
nant neoplasmic samples were carefully microdissected
under a microscope to exclude surrounding normal
tissue. BRAF mutation was also assessed both on touch
cytologic samples directly obtained from specimens
immediately after surgery, and on May–Grunwald
Giemsa- or Papanicolau-stained, routine FNAB.
Thyroid carcinoma cell lines NPA (homozygous
BRAF mutation at the nucleotide 1799) and WRO
(homozygous wild-type BRAF) were kindly donated by
M. Nagao (Tokyo, Japan) (31). All cell lines were cul-
tured in petri dishes in 5% CO2 atmosphere at 37 8C,
in Ham’s F-12 medium supplemented with 10% fetal
calf serum (FCS). Study approval was obtained from
the institutional review board.
Genomic DNA extraction
For nucleic acid extraction from paraffin-embedded tis-
sues, 5mm sections were immersed in xylene for
30min to remove paraffin, and washed in absolute and
then in70%ethanol. All sampleswere subjected to diges-
tion with 0.5% SDS and 0.5mg/ml proteinase K at 37 8C
overnight, extracted with phenol and precipitated with
ethanol in the presence of sodium acetate. Genomic
DNA extraction from FNAB specimens and from thyroid
tumor cell lines was conducted by TRI Reagent (Sigma)
(500ml for FNAB and 1ml/10 cm2 of culture plate sur-
face area), according to themanufacturer’s instructions.
DNAconcentrationwas quantitated byA 260 absorbance
with a BioPhotometer (Eppendorf, Hamburg, Germany).
Genomic DNA (50–100 ng/sample) was used as a
template.
Table 1 BRAFV600E prevalence in the literature. Data are expressed as positive/number of cases (percentage).
References Benign lesions PTC PTC classic PTC follicular variant FTC
(15) n.d. 28/78 (35.8) n.d. n.d. 0/46 (0)
(21) 0/111 (0) 45/119 (37.8) n.d. n.d. 0/32 (0)
(19) 0/20 (0) 49/170 (28.8) n.d. n.d. 0/11 (0)
(18) 0/24 (0) 21/56 (37.5) n.d. n.d. FA 0/18 (0)
(33) n.d. 41/114 (35.9) 28/53 (52.8) 0/32 (0) n.d.
(22) 0/34 (0) 8/18* (44.4) n.d. n.d. 0/5 (0)
(24) 0/15 (0) 18/56 (32.1) 18/47 (38.3) 0/6 (0) 0/5 (0)
(23) 0/6 (0) 24/60 (40) 19/35 (54.2) 4/19 (21.0) 0/5 (0)
Present study by MASA 0/5 (0) 19/43 (44.2) 14/31 (45.2) 5/12 (41.7) 0/27 (0)
FA, follicular adenoma; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma.
*Only sporadic PTC.
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PCR amplification of exon 15 segment of the
BRAF
Two primers (forward, 50-TCATAATGCTTGCTCTGAT-
AGGA-30; reverse, 50 GGCCAAAATTTAATCAGTGGA-
30), as described previously (8), were used to amplify
a 224 bp fragment of the exon 15 of BRAF containing
the site in which T1799A mutation occurs. PCR reac-
tions were performed in 25ml of 1.5mM MgCl2, with
200mM deoxynucleoside triphosphates, 50–100 ng
genomic DNA, 0.5mM of each primer and 2.5U Euro-
Taq DNA polymerase (EuroClone, Celbio, Italy).
Thirty-five cycles with annealing temperatures opti-
mized at 58 8C were used to apply the PCR product.
Amplification products were separated on 1.2% agarose
gel and visualized by ethidium bromide staining.
MASA
Two different forward primers with substitution of a
single base at the end of the primer (50-GTGATTTTGG-
TCTAGCTACAGT-30 and 50-GTGATTTTGGTCTAGCT-
ACAGA-30) were designed to amplify the wild-type
allele or BRAF T1799A transversion mutation respect-
ively. The sequence of the reverse primer was the same
as used before.
ThePCRreactionswereperformedseparately inaPTC-
100Peltier Thermal Cycler (MJ Research Bio-Rad,Milan,
Italy), including an initial denaturation of 2min at 94 8C
and subsequent denaturation for30 sat94 8C, annealing
for 30 s at 58 8C and extension for 30 s at 72 8C. All
samples were re-examined for BRAF mutation at least
three times.
SSCP
SSCP is a method of detecting single base mutations by
the mobility of the single-strand DNA under PAGE.
Single base mutations may disrupt secondary structure
of the single-strand DNA and lead to changes in mobi-
lity through polyacrylamide gel mash. PCR products of
exon 15 of the BRAF gene were diluted 1:1 with dena-
turing solution (1% (w/v) bromophenol blue and 99%
formamide) at 95 8C for 5min and immediately placed
on ice to prevent reannealing of the single-strand pro-
ducts. Electrophoresis was carried out on the GenePhor
Electrophoresis Unit with GeneGel Excel 12.5/24
(Amersham) at 15 8C, 650V, 30mA and 15 W for
120min. Gels were stained with PlusOne silver staining
kit (Amersham) according to the manufacturer’s
instructions.
Sequencing
Genomic PCR products and/or aberrant SSCP bands
were sequenced. PCR reactions in 25ml of final
volume were performed as described above. A 2ml ali-
quot was run on an agarose gel to verify the adequacy
of the reaction, and the rest was used for direct sequen-
cing. Sequences were performed with the ET-termin-
ators kit (Amersham) and run on the MegaBACE 500
(Amersham) capillary sequencer.
Sequences were compared by the BLAST program:
www.ncbi.nlm.nih.gov/BLAST/ (32).
The PTC cell line NPA was used as a positive control
for BRAF T1799A mutation, and the follicular thyroid
carcinoma cell line WRO was used as a control for wild-
type BRAF gene.
Statistical analysis
Results were analyzed by the chi-square of indepen-
dence test or the t-test with Prism (Version 3.00 for
Windows; GraphPad Software, San Diego, CA, USA).
The level of significance was set at P , 0.05.
Results
Detection of BRAF mutation by SSCP, DNA
sequencing and MASA
To determine whether different methods to detect
T1799A transversion mutation at exon 15 of BRAF
gene have different sensitivity and to determine which
method is the most sensible, we analyzed a mixture of
DNA by SSCP, direct DNA sequencing of PCR products
and MASA. The DNA was extracted from WRO cells
harboring wild-type BRAF gene and from NPA cells
homozygous for BRAFmutation. The two DNA extracts
were mixed together at variable ratio, and results
obtained by the three methods were compared. The
analysis by SSCP revealed that the product of PCR con-
taining the transversion was clearly detectable as a
faster band only when the DNA from NPA cells was
60% or more in the DNA mixture (Fig. 1A). At lower
concentration, a faint band corresponding to the
mutant allele was sometimes visible. The sensitivity of
direct sequencing of the PCR products of the DNA mix-
ture was comparable to that of SSCP, as, at concen-
trations lower than 60%, BRAF T1799A was not
detected (Fig. 1B). MASA proved to be the most sensi-
tive of the three methods. Each of the two forward pri-
mers used generated only the corresponding specific
PCR product from wild-type BRAF or when thymidine
replaced adenosine at nucleotide position 1799 in the
BRAF sequence. A clear band corresponding to BRAF
T1799A was always evident also at the lower concen-
tration tested (Fig. 1C). MASA analysis was performed
also on DNA extracted from five frozen tissues, five
fresh cytologic specimens and four cytologic specimens
obtained from fixed and stained archival glass slides. In
all cases, MASA proved to be a reliable and rapid
method to search for BRAF mutation (Fig. 2). Cytologic
material was extracted also from glass slides of
inadequate FNAB (Fig. 2D). Although the number of
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cells was insufficient for the pathologist’s morphologic
assessment, MASA analysis was feasible. This result
suggests that the search for BRAF mutations by
MASA may represent a diagnostic adjunctive tool in
inadequate FNAB sampling.
Prevalence of BRAFV600E in paraffin-embedded
thyroid tumors
By MASA assay, the presence of BRAF mutation was
investigated in a series of 78 paraffin-embedded thyroid
Figure 1 Sensitivity of SSCP, DNA sequencing and MASA. Total DNA extracted from NPA and WRO cells was mixed at variable ratio.
The DNA mixtures were analyzed by SSCP (A), direct DNA sequencing of PCR products (B) or MASA (C) to search for T1799A trans-
version mutation at exon 15 of the BRAF gene. NPA and WRO cells harbor a homozygous BRAF T1799A mutation and wild-type
BRAF respectively. Circles indicate nucleotide at 1799 position.
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tissues, including five normal thyroids, three follicular
adenomas, 27 follicular carcinomas and 43 papillary
carcinomas (Table 2). No mutations of BRAF were
detected in the normal thyroid tissues, follicular adeno-
mas or follicular carcinomas. In the 43 papillary thyroid
cancers studied, 19 displayed BRAF mutation (44.2%).
Further analysis by papillary cancer type showed that
14/31 classic forms (45.2%) and 5/12 (41.7%) follicular
variants were positive for the mutation.
Correlation analysis between BRAF mutation
and clinical features
We examined the correlation between the presence of
BRAF mutation and various clinicopathologic features
in patients with papillary thyroid cancer. Clinical
parameters considered were age at appearance, gender,
tumor volume, multicentricity, pTNM classification and
stage (Table 3). For 22 patients, recurrence was also con-
sidered. The analysis considered overall the papillary thyr-
oid cancer and the classic form or the follicular variant.
No statistically significant correlation was found
between BRAF mutation and age at appearance,
gender of the patients, multicentricity of the tumor,
volume, pTNM classification and stage. However, there
was a significant correlation between BRAFV600E
mutation and absence of node metastasis (P ¼ 0.011;
chi-square of independence test). A postoperative
follow-up period of 4–11 years (median 6 years) was
considered for 22 patients. All patients were treated
with total thyroidectomy, followed by 131-iodine
therapy and thyroid-stimulating hormone (TSH)-sup-
pressive therapy with levothyroxine sodium (LT4).
Periodically, serum thyroglobulin concentration under
LT4 therapy was measured. The follow-up was com-
pleted with serum thyroglobulin measurement upon
rhTSH subministration and neck ultrasound. Patients
were considered free of disease when thyroglobulin was
undetectable (,2ng/ml) and ultrasound was negative.
Withdrawal of LT4 therapy followed by 131-iodine
whole-body scan was performed in patients with detect-
able thyroglobulin and/or positive neck ultrasound.Nine
patients of 11 positive for BRAFmutation remained free
of disease, and only two recurred. Of the 11 patients
negative for BRAF T1799A transversion mutation,
seven remained free of disease and four recurred. How-
ever, no significant correlation between BRAFmutation
and disease outcome was found (P , 0.5; chi-square of
independence test).
Discussion
To date, oncogenic mutations of BRAF have been con-
fined to exon 15, resulting in a valine-to-glutamate
substitution at residue 600 (8, 16–18). The presence
of BRAF mutation has been investigated in several
studies with consensus on many findings but also
reporting some relevant conflicting results. General
agreement has been reached on the restricted
Figure 2 MASA analysis of thyroid specimens. MASA analysis
was performed on papillary thyroid cancers from paraffin-
embedded specimens (A), fresh tissues (B) and fresh cytologic
material (C). (D) MASA analysis performed on cytologic material
obtained from archival glass slides of inadequate FNAB.
Table 2 BRAF prevalence as determined by MASA analysis.
Number of cases (percentage).
BRAF mutation
þ –
Overall 19 (44.2) 24 (55.8)
PTC 43 Classic 31 14 (45.2) 17 (54.8)
Thyroid Follicular 12 5 (41.7) 7 (58.3)
Tumors FTC 27 0 27 (0)
78 FA 3 0 3 (0)
NT 5 0 5 (0)
PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; FA,
follicular adenoma; NT, normal thyroid.
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expression of BRAF mutation in papillary tumors and
undifferentiated with papillary component tumors in
the thyroid gland (21). In view of its selective
expression, BRAFV600E is an ideal hallmark of thyroid
cancer with papillary component.
However, although its specificity to differentiate
benign nodules from thyroid cancer is 100%, its sensi-
tivity is ambiguous, as its prevalence varies in the
different studies from 28.8% to 44.2% (Table 1). The
detection of BRAF mutation in cytologic specimens
from thyroid fine-needle aspiration has been proposed
to improve the diagnostic accuracy of this procedure,
identifying papillary carcinomas with indeterminate
cytologic findings. In this regard, sensitivity of BRAF
T1799A transversion detection strictly depends upon
prevalence of BRAF mutation. From a clinical stand-
point, an indeterminate prevalence biases the appli-
cation of BRAF T1799A detection as a reliable tool to
improve preoperative diagnosis. Different prevalences
observed in the literature might reflect the heterogen-
eity of sample groups analyzed or might arise from
the application of methods with different sensibility.
Others have hypothesized that different prevalence
with regard to histologic type of PTC might be respon-
sible for different overall BRAFV600E prevalence in the
PTC series analyzed. In two different studies, BRAF
mutation was not detected in any of the 38 cases of
PTC follicular variant analyzed (24, 33). In these
studies, BRAF mutations were sought by direct DNA
sequencing of PCR products, preceded by SSCP analysis
in the study by Trovisco et al. (33). Combination of
these two methods was used also in the study by
Puxeddu et al. (23) but with totally different results,
as BRAF mutation was detected in 4/19 specimens of
PTC follicular variant. In our study, the prevalence of
BRAF mutation was similar in classic and follicular var-
iants of PTC (45.2% and 41.7% respectively; P ¼ 0.99).
Hence, while different classic form/follicular variant
ratio in the PTC series analyzed might account for
only minimal discrepancies in overall PTC prevalence,
we have to explain why findings within follicular var-
iant are so conflicting. Searching for BRAF T1799A
in serial dilutions of DNA extracted from NPA in DNA
from WRO cells revealed that sensibility of SSCP and
DNA sequencing is quite low. Both methods could
detect this mutation only in samples containing more
then 40% of cells harboring homozygous BRAF
mutation. Assuming heterozygosity for the alleles in
primitive tumor cells, these methods are unable to
detect the mutation in heterogeneous samples. The
need for a more sensitive method to lower false-negative
results arises also from the possibility that PTC speci-
mens are contaminated by normal surrounding or
intranodular cells. Similarly, if BRAF mutation is
restricted to the papillary component of thyroid
tumors, as suggested by some authors (21), then this
mutation can be detected in follicular variant of PTC
only when the papillary component is largely prevalent.
The possibility that BRAF mutation is not present in all
cells within a tumor is worth consideration. Unger et al.
(34) searched for RET/PTC rearrangements in papillary
thyroid cancers of Ukrainian patients exposed to radi-
ation after the Chernobyl nuclear accident. They
demonstrated that only a small proportion of cells har-
bored the rearrangement, supporting the idea of het-
erogeneity within the tumor mass. This finding
suggests either that these tumors are of polyclonal
origin, or that RET rearrangements are a subclonal
event (35). As for RET/PTC, theoretically, BRAF
mutation could also be present only in a proportion
Table 3 Correlation between BRAF mutation and clinicopathological parameters in 43 cases of papillary thyroid cancer.
BRAFV600E positive BRAFV600E negative P
Age median 40.2 43.1 0.5*
Gender 0.76
male 2/5 3/5
female 16/32 16/32
Tumor volume cm3 (mean^S.D.) 15.3^26 12.9^14 0.38*
Multicentricity 4 5 0.77
PTNM
T1 1 2 0.59
T2 10 3 0.05
T3 2 2 0.96
T4 5 12 0.11
N0 18 12 0.21
N1 0 7 0.01
M0 18 18 0.87
M1 0 1 0.33
Stage
1 13 11 0.59
2 4 2 0.30
3 1 5 0.12
4 0 1 0.33
Analysis was by chi-square of independence test or by the t-test (*).
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of tumor cells. The MASA assay we designed to detect
BRAF transversion mutation in thyroid samples
proved to be a method more sensitive than SSCP and
DNA sequencing of PCR products. This may account
for the higher prevalence of BRAFV600E we found in
overall PTC as well as in the follicular variant. The
BRAF prevalence determined in our study is also
higher than in Xu et al.’s study (18), in which
MASA-PCR used a primer with substitution of two
bases at the 30-end, designed to amplify only the
BRAF mutant allele. Although two nucleotide
mismatches may reduce the annealing and amplifica-
tion of wild-type allele, thus reducing false-positive
results, this may yield more false-negative results
than using a primer with only one base substitution
at the 30-end, as we did in our study. Primers with
one base substitution (T/A) used in our MASA assay
warrant a perfect annealing for both wild-type and
mutant alleles. The absence of mutations found in 35
benign lesions or follicular carcinomas demonstrates
the specificity and reliability of the method employed.
Some 10–15% of FNABs yielded indeterminate diagno-
sis because of inadequate drawing. The number of cells
necessary for nucleic acid analysis is much lower than
that necessary for morphologic assessment. Therefore,
detection of oncogenes on FNAB specimens has been
proposed as a diagnostic adjunctive tool in inadequate
FNAB. Our study suggests that the search for BRAF
mutations by MASA in cytologic material extracted
from glass slides of inadequate FNABs may represent
a valid diagnostic adjunctive tool. The method is
rapid and easy to perform; however, some limits must
be considered. Only a predefined mutation can be
detected by MASA whereas new mutations remain
hidden. Its effectiveness in the diagnosis of papillary
carcinoma is limited by the BRAF prevalence in this
type of cancer. In our institution, 24 inadequate
FNABs were analyzed by MASA for BRAF mutation.
One sample was found to be positive, and the patient
underwent thyroidectomy. The diagnosis of PTC of clas-
sic form was confirmed by histology. The cancer was
not excluded in the BRAF-negative samples because
this mutation accounts for only 44.2% of PTC and
even less when all types of thyroid cancer are con-
sidered. Therefore, to increase the significance of gen-
etic analysis in indeterminate FNABs, BRAF mutation
should be sought together with other oncogenes
(RET/PTC, Trk). To date, while a positive MASA assay
affects the diagnosis and the consequent therapy, the
negative search for BRAFV600E does not change a
therapeutic decision based on clinical parameters.
Early studies on BRAF expression and clinicopatholo-
gic parameters reported a significant association with
distant metastasis, extrathyroidal extension and more
advanced clinical stage, suggesting that BRAF
mutation contributes to the development of an aggres-
sive phenotype (19, 21). However, these results have
not been confirmed by later studies (18, 23, 24). Our
analysis of clinicopathologic parameters at diagnosis
and at 4–11-year follow-up confirmed the lack of
association between BRAFV600E and aggressive clinical
behavior. In our opinion, different sensitivity of
methods used to detect BRAF mutation and limitation
in size of the studies may account for such discordant
findings. Our data suggest the existence of a positive
correlation between BRAF mutation and the absence
of node metastasis. However, although the association
was statistically significant, it must be taken into
account that only seven cases presented node
metastasis. Such a small number imposes caution in
drawing conclusions.
In conclusion, our study demonstrates a higher preva-
lence ofBRAFmutation in PTC and that this mutation is
present in the classic form and in the follicular variant
with similar frequency. No significant correlation was
found between BRAFV600E and aggressive clinical beha-
vior. MASA-PCR proved to be a specific, sensitive and
reliable method to detect BRAF transversion mutation
in small quantities of DNA extracted from different
sources, including cytologic material obtained either
fresh or from archival glass slides. We propose this
method as a useful tool to improve the accuracy of preo-
perative diagnosis in identifying PTC from biopsies with
indeterminate cytologic findings.
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